Socazolimab injection | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Company: Zhaoke (Guangzhou) Oncology Pharmaceutical Co., Ltd.
Medicine type: Biologic
Therapeutic area: Oncology
Indications recorded in the public source: For recurrent or metastatic cervical cancer after failure of platinum-based chemotherapy. Conditional approval is based on a surrogate endpoint. Clinical endpoint data are not yet available, and efficacy and safety require further post-approval confirmation. Full approval depends on ongoing confirmatory clinical trials establishing clinical benefit with socazolimab.
Indication source and scope: Source date(s): 2025. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label. Additional indications may be supported by newer announcements or submissions rather than the older full label; see the indication sources.
Prescribing-information limitations: Indications checked against an official public submission. The full original prescribing information is still unavailable.
China availability status: Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status: Market-by-market verification pending.
Insurance classification: Not matched in the 2025 national list; manual review pending
Insurance edition: 2025 edition; effective 1 January 2026
Insurance verification notes: No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.

Sources

Open the interactive record, public price references and discussions